JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.9 -4.04

Overview

Share price change

24h

Current

Min

1.8599999999999999

Max

1.99

Key metrics

By Trading Economics

Income

384M

-42M

Sales

2.6M

40M

Profit margin

-105.442

Employees

575

EBITDA

367M

-36M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+0.51% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

69M

487M

Previous open

5.94

Previous close

1.9

News Sentiment

By Acuity

9%

91%

8 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 paź 2025, 23:55 UTC

Hot Stocks

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 paź 2025, 23:49 UTC

Earnings

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 paź 2025, 21:40 UTC

Earnings

Waste Connections 3Q Revenue Rises

21 paź 2025, 21:14 UTC

Earnings
Major Market Movers

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 paź 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 paź 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

DraftKings to Launch Prediction Markets Platform

21 paź 2025, 20:38 UTC

Earnings

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 paź 2025, 20:35 UTC

Earnings

Capital One 3Q Sales, Profit Jump

21 paź 2025, 20:32 UTC

Earnings

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 paź 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 paź 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 paź 2025, 23:39 UTC

Market Talk

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 paź 2025, 23:36 UTC

Market Talk

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 paź 2025, 22:55 UTC

Acquisitions, Mergers, Takeovers

Scentre Says This Forms Part of Capital Management Strategy

21 paź 2025, 22:55 UTC

Acquisitions, Mergers, Takeovers

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 paź 2025, 22:54 UTC

Acquisitions, Mergers, Takeovers

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 paź 2025, 21:09 UTC

Market Talk
Earnings

Netflix Creators Have Started Using AI in Production -- Market Talk

21 paź 2025, 20:58 UTC

Market Talk
Earnings

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 paź 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

21 paź 2025, 20:43 UTC

Earnings

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 paź 2025, 20:41 UTC

Earnings

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 paź 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 paź 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 paź 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 paź 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 paź 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 paź 2025, 20:32 UTC

Acquisitions, Mergers, Takeovers

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 paź 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 paź 2025, 20:29 UTC

Earnings

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

0.51% upside

12 Months Forecast

Average 1.99 USD  0.51%

High 3 USD

Low 1.25 USD

Based on 7 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

3

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

8 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat